Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
1.
Pediatr Infect Dis J ; 40(7): e274-e276, 2021 07 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1700567

RESUMEN

Underlying mechanisms on the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and neurologic complications are still poorly understood. Cases of Guillain-Barré Syndrome (GBS) have been linked to the SARS-CoV-2 infection as the result of dysregulated immune response with damage in neuronal tissues. In the current report, we present the first pediatric case of GBS with detection of SARS-CoV-2 in the cerebrospinal fluid (CFS). This unique case of COVID-19-associated GBS with detection of SARS-CoV-2 RNA in the CSF indicates direct viral involvement inducing peripheral nerve inflammation.


Asunto(s)
COVID-19/líquido cefalorraquídeo , COVID-19/diagnóstico , Síndrome de Guillain-Barré/complicaciones , ARN Viral/líquido cefalorraquídeo , Adolescente , COVID-19/complicaciones , Cauda Equina/diagnóstico por imagen , Cauda Equina/patología , Cauda Equina/virología , Femenino , Síndrome de Guillain-Barré/virología , Humanos , Inflamación/virología , Imagen por Resonancia Magnética , SARS-CoV-2/aislamiento & purificación
2.
Brain ; 144(11): 3392-3404, 2021 12 16.
Artículo en Inglés | MEDLINE | ID: covidwho-1606276

RESUMEN

In the wake of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, an increasing number of patients with neurological disorders, including Guillain-Barré syndrome (GBS), have been reported following this infection. It remains unclear, however, if these cases are coincidental or not, as most publications were case reports or small regional retrospective cohort studies. The International GBS Outcome Study is an ongoing prospective observational cohort study enrolling patients with GBS within 2 weeks from onset of weakness. Data from patients included in this study, between 30 January 2020 and 30 May 2020, were used to investigate clinical and laboratory signs of a preceding or concurrent SARS-CoV-2 infection and to describe the associated clinical phenotype and disease course. Patients were classified according to the SARS-CoV-2 case definitions of the European Centre for Disease Prevention and Control and laboratory recommendations of the World Health Organization. Forty-nine patients with GBS were included, of whom eight (16%) had a confirmed and three (6%) a probable SARS-CoV-2 infection. Nine of these 11 patients had no serological evidence of other recent preceding infections associated with GBS, whereas two had serological evidence of a recent Campylobacter jejuni infection. Patients with a confirmed or probable SARS-CoV-2 infection frequently had a sensorimotor variant 8/11 (73%) and facial palsy 7/11 (64%). The eight patients who underwent electrophysiological examination all had a demyelinating subtype, which was more prevalent than the other patients included in the same time window [14/30 (47%), P = 0.012] as well as historical region and age-matched control subjects included in the International GBS Outcome Study before the pandemic [23/44 (52%), P = 0.016]. The median time from the onset of infection to neurological symptoms was 16 days (interquartile range 12-22). Patients with SARS-CoV-2 infection shared uniform neurological features, similar to those previously described in other post-viral GBS patients. The frequency (22%) of a preceding SARS-CoV-2 infection in our study population was higher than estimates of the contemporaneous background prevalence of SARS-CoV-2, which may be a result of recruitment bias during the pandemic, but could also indicate that GBS may rarely follow a recent SARS-CoV-2 infection. Consistent with previous studies, we found no increase in patient recruitment during the pandemic for our ongoing International GBS Outcome Study compared to previous years, making a strong relationship of GBS with SARS-CoV-2 unlikely. A case-control study is required to determine if there is a causative link or not.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/epidemiología , Adulto , Anciano , Estudios de Cohortes , Femenino , Síndrome de Guillain-Barré/virología , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , SARS-CoV-2
3.
Diabetes Metab Syndr ; 15(6): 102326, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1555243

RESUMEN

BACKGROUND AND AIMS: The COVID-19 pandemic has turned the world topsy turvy since its emergence and has claimed innumerable lives worldwide. Neurological manifestations of the disease have raised several eyebrows around the world among which Guillain-Barré syndrome (GBS) deserve special mention. Although majority of the cases of the coronavirus disease 2019 (COVID-19) present with respiratory symptoms, extrapulmonary manifestations are being increasingly reported. We conducted this study to analyze detailed clinical presentations and outcome in a series of eight cases (n = 8) with COVID-19 associated GBS. METHODS: An observational prospective study was conducted among patients with post-infectious/para-infectious GBS. 8 patients were subclassified into acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN) as per electrodiagnostic criteria and were followed up from admission to 6 months post discharge, to obtain a comprehensive clinical profile and outcome in these patients. RESULTS: The diagnosis of GBS was confirmed as per Asbury criteria, supported by electrodiagnostic features in nerve conduction velocity test. Among the series of 8 patients, 3 were diagnosed as AIDP, 3 had AMAN and the remaining 2 patients had AMSAN. 3 patients of GBS were afebrile and were diagnosed as COVID-19 after a positive assay on routine screening. Cerebro-spinal fluid analysis for SARS-Cov-2 RT-PCR and serum anti-ganglioside antibodies were negative in all the patients. CONCLUSION: GBS in patients with COVID-19 should be differentiated from critical illness neuropathy and myopathy. Early diagnosis is important as it is associated with poor outcome and prolonged invasive ventilation.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Adulto , Anciano , Femenino , Síndrome de Guillain-Barré/clasificación , Síndrome de Guillain-Barré/fisiopatología , Síndrome de Guillain-Barré/terapia , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Respiración Artificial
4.
Nat Med ; 27(12): 2144-2153, 2021 12.
Artículo en Inglés | MEDLINE | ID: covidwho-1483142

RESUMEN

Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 (n = 20,417,752) or BNT162b2 (n = 12,134,782), and after a SARS-CoV-2-positive test (n = 2,005,280). There was an increased risk of Guillain-Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15-3.92 at 15-21 days after vaccination) and Bell's palsy (IRR, 1.29; 95% CI: 1.08-1.56 at 15-21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12-1.71 at 15-21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain-Barré syndrome (IRR, 2.32; 95% CI: 1.08-5.02 at 1-28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain-Barré syndrome (IRR, 5.25; 95% CI: 3.00-9.18). Overall, we estimated 38 excess cases of Guillain-Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.


Asunto(s)
Vacuna BNT162/efectos adversos , Parálisis de Bell/epidemiología , COVID-19/patología , ChAdOx1 nCoV-19/efectos adversos , Síndrome de Guillain-Barré/epidemiología , Accidente Cerebrovascular Hemorrágico/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Vacuna BNT162/inmunología , Parálisis de Bell/virología , COVID-19/diagnóstico , COVID-19/inmunología , ChAdOx1 nCoV-19/inmunología , Inglaterra/epidemiología , Femenino , Síndrome de Guillain-Barré/virología , Accidente Cerebrovascular Hemorrágico/virología , Hospitalización/estadística & datos numéricos , Humanos , Masculino , Persona de Mediana Edad , Enfermedades del Sistema Nervioso/epidemiología , Enfermedades del Sistema Nervioso/virología , SARS-CoV-2/inmunología , Escocia/epidemiología , Adulto Joven
6.
Tuberk Toraks ; 69(2): 242-246, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: covidwho-1444456

RESUMEN

COVID-19, caused by severe acute respiratory syndrome coronavirus-2, typically presents with respiratory symptoms and fever, but still a variety of clinical presentations have been reported. In this study, it was aimed to report a case of COVID-19 with an atypical presentation and an atypical course. As well, the recovery phase was complicated with GBS and consequently cytomegalovirus infection. It should be kept in mind that patients with COVID-19 severe disease need to be followed for neurological and other complications which may arise during the course of critical illness.


Asunto(s)
COVID-19/diagnóstico , Síndrome de Guillain-Barré/diagnóstico , SARS-CoV-2 , Anciano , COVID-19/epidemiología , Diagnóstico Diferencial , Síndrome de Guillain-Barré/virología , Humanos , Masculino , Pandemias , Turquía/epidemiología
7.
J Neurovirol ; 27(5): 797-801, 2021 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1432669

RESUMEN

Guillain-Barré syndrome (GBS) is an ascending demyelinating polyneuropathy often associated with recent infection. Miller Fisher syndrome represents a variant with predominant facial and cranial nerve involvement, although Miller Fisher and Guillain-Barré overlap syndromes can occur. Guillain-Barré spectrum syndromes have been thought to be rare among solid organ transplant recipients. We describe an immunocompromised patient with a liver transplant who presented with ophthalmoplegia and bulbar deficits. His symptoms rapidly progressed to a state of descending paralysis involving the diaphragm; he then developed acute respiratory failure and eventually developed quadriparesis. Electromyography and a nerve conduction study demonstrated a severe sensorimotor axonal polyneuropathy consistent with Miller Fisher variant Guillain-Barré syndrome. Despite several negative nasopharyngeal swabs for COVID-19 polymerase chain reaction, a serology for SARS-CoV-2 IgG was positive. He was diagnosed with Miller Fisher-Guillain-Barré overlap syndrome with rapid recovery following treatment with plasma exchange. Although Guillain-Barré is a rare complication in solid organ transplant recipients, this case highlights the importance of rapid diagnosis and treatment of neurologic complications in transplant patients. Furthermore, it demonstrates a possible case of neurological complications from COVID-19 infection.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/inmunología , Síndrome de Guillain-Barré/virología , Síndrome de Miller Fisher/inmunología , Síndrome de Miller Fisher/virología , Síndrome de Guillain-Barré/terapia , Humanos , Huésped Inmunocomprometido , Trasplante de Hígado , Masculino , Persona de Mediana Edad , Síndrome de Miller Fisher/terapia , Plasmaféresis , SARS-CoV-2 , Receptores de Trasplantes
8.
J Med Virol ; 93(9): 5432-5437, 2021 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-1363681

RESUMEN

This case series describes three patients affected by severe acute respiratory syndrome coronavirus 2, who developed polyradiculoneuritis as a probable neurological complication of coronavirus disease 2019 (COVID-19). A diagnosis of Guillain Barré syndrome was made on the basis of clinical symptoms, cerebrospinal fluid analysis, and electroneurography. In all of them, the therapeutic approach included the administration of intravenous immunoglobulin (0.4 gr/kg for 5 days), which resulted in the improvement of neurological symptoms. Clinical neurophysiology revealed the presence of conduction block, absence of F waves, and in two cases, a significant decrease in amplitude of compound motor action potential cMAP. Due to the potential role of inflammation on symptoms development and prognosis, interleukin-6 (IL-6) and IL-8 levels were measured in serum and cerebrospinal fluid during the acute phase, while only serum was tested after recovery. Both IL-6 and IL-8 were found increased during the acute phase, both in the serum and cerebrospinal fluid, whereas 4 months after admission (at complete recovery), only IL-8 remained elevated in the serum. These results confirm the inflammatory response that might be linked to peripheral nervous system complications and encourage the use of IL-6 and IL-8 as prognostic biomarkers in COVID-19.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/complicaciones , Interleucina-6/líquido cefalorraquídeo , Interleucina-8/líquido cefalorraquídeo , Insuficiencia Respiratoria/complicaciones , SARS-CoV-2/patogenicidad , Potenciales de Acción/efectos de los fármacos , Enfermedad Aguda , Anciano , Antibacterianos/uso terapéutico , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , COVID-19/líquido cefalorraquídeo , COVID-19/virología , Convalecencia , Darunavir/uso terapéutico , Combinación de Medicamentos , Síndrome de Guillain-Barré/líquido cefalorraquídeo , Síndrome de Guillain-Barré/tratamiento farmacológico , Síndrome de Guillain-Barré/virología , Humanos , Hidroxicloroquina/uso terapéutico , Inmunoglobulinas Intravenosas/uso terapéutico , Interleucina-6/sangre , Interleucina-8/sangre , Lopinavir/uso terapéutico , Masculino , Conducción Nerviosa/efectos de los fármacos , Sistema Nervioso Periférico/efectos de los fármacos , Sistema Nervioso Periférico/patología , Sistema Nervioso Periférico/virología , Pronóstico , Insuficiencia Respiratoria/líquido cefalorraquídeo , Insuficiencia Respiratoria/tratamiento farmacológico , Insuficiencia Respiratoria/virología , Ritonavir/uso terapéutico , SARS-CoV-2/efectos de los fármacos , Tratamiento Farmacológico de COVID-19
10.
J Neurovirol ; 27(4): 662-665, 2021 08.
Artículo en Inglés | MEDLINE | ID: covidwho-1338290

RESUMEN

Guillain-Barré syndrome (GBS) is a peripheral nervous system disease caused by an immune-mediated inflammatory mechanism, usually triggered by a previous infectious process or vaccine; its typical presentation is a rapid and progressive bilateral limb hyposthenia, associated with sensory deficits and reduction or absence of osteotendinous reflexes. However, also autonomic nervous system can be involved with heart rate fluctuations, blood pressure instability, pupillary dysfunction, and urinary retention. Since the beginning of COVID-19 pandemic, GBS has been reported among neurological complications of SARS-CoV-2 infection, although etiopathological mechanisms still have to be clearly defined. We report the case of a 79-year-old man with multiple comorbidities, including diabetes, who was affected by SARS-CoV-2 interstitial pneumonia and developed dysautonomic symptoms after 10 days of hospitalization. A neurological evaluation was performed, and GBS was considered as a possible cause of the clinical manifestations. This hypothesis was confirmed by electrophysiological study and further supported, ex-juvantibus, by the satisfactory response to immunoglobulin treatment. In our opinion, this case of pure dysautonomic presentation of GBS in a SARS-CoV-2 positive patient is relevant because it suggests to consider GBS upon SARS-CoV-2 infection even if the symptoms have uncommon characteristics (e.g., pure vegetative manifestations) and if there are confounding factors which could lead to a misdiagnosis (e.g., old age, SARS-CoV-2 infection consequences and diabetes).


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/virología , Disautonomías Primarias/virología , Anciano , Síndrome de Guillain-Barré/complicaciones , Humanos , Masculino , Disautonomías Primarias/etiología , SARS-CoV-2
11.
Neurosci Lett ; 759: 136040, 2021 08 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1322284

RESUMEN

Despite a likely underestimation due to the many obstacles of the highly infectious, intensive care setting, increasing clinical reports about COVID-19 patients developing acute paralysis for polyradiculoneuritis or myelitis determine additional impact on the disease course and outcome. Different pathogenic mechanisms have been postulated basing on clinical, laboratory and neuroimaging features, and response to treatments. Here we provide an overview with insights built on the available reports. Besides direct viral pathogenicity, a crucial role seems to be represented by immune-mediated mechanisms, supporting and further characterizing the already hypothesized neurotropic potential of SARS-CoV-2 and implying specific treatments. Proper clinical and instrumental depiction of symptomatic cases, as well as screening for their early recognition is advocated.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Mielitis/epidemiología , Mielitis/virología , Síndrome de Guillain-Barré/patología , Humanos , Mielitis/patología , SARS-CoV-2
12.
J Neuroimmunol ; 357: 577605, 2021 08 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1313260

RESUMEN

Guillain-Barré syndrome (GBS) is an immune-mediated peripheral neuropathy characterized by a typical post-infectious profile. Some post-Zika virus and post-severe acute respiratory syndrome-related coronavirus-2 GBS cases have been reported to occur with very short intervals between the infection and GBS onset. Evaluating 161 GBS patients consecutively admitted to two Italian Regional Hospitals between 2003 and 2019, we found that the only three with an antecedent influenza A (H1N1) virus infection developed GBS within an interval of less than 10 days from the influenza illness. The two of them with a demyelinating subtype promptly recovered without therapy. Overall, the parainfectious cases add heterogeneity to the GBS category, warranting pathogenetic insights.


Asunto(s)
Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/etiología , Subtipo H1N1 del Virus de la Influenza A/aislamiento & purificación , Gripe Humana/complicaciones , Gripe Humana/diagnóstico , Adolescente , Femenino , Síndrome de Guillain-Barré/virología , Humanos , Masculino , Persona de Mediana Edad
14.
J Neurovirol ; 27(5): 802-805, 2021 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1245766

RESUMEN

Acute respiratory distress syndrome (ARDS) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is spreading around the world. Patients with coronavirus disease 2019 (COVID-19) typically present fever, cough, and respiratory illnesses. It has been revealed that the comorbidities can turn it into severe types, and the managements meet unpredicted complications. Here, we report a case of coronavirus disease 2019 (COVID-19) coincidence with confirmed acute Guillain-Barré syndrome (GBS). Ten days after admission and therapeutic process, the patient developed autonomic dysfunction. Despite respiratory support and receiving intravenous immunoglobulin, the patient died due to cardiac arrest. Albeit it is yet scientifically doubtful, there are raising concerns toward a possible association between GBS and SARS-CoV-2 infection, demonstrating potential neurological symptoms of COVID-19.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Anciano , Resultado Fatal , Humanos , Masculino , SARS-CoV-2
15.
J Neuroimmunol ; 356: 577590, 2021 07 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1217589

RESUMEN

A 50-years old male presented with quadriplegia and paresthesia and was diagnosed as Guillain-Barré syndrome (GBS). He was found positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) six weeks prior to the onset of weakness. GBS disability score was 4. Electrophysiology showed acute inflammatory demyelinating polyradiculopathy. Anti-SARS-CoV-2 IgG was found positive. Immunological tests for Campylobacter jejuni, Zika virus, Hepatitis E virus, Herpes Simplex virus, Haemophilus influanzae and Mycoplasma pneumoniae were negative. Patient received standard dose of intravenous immunoglobulin and after six months had almost complete recovery of muscle power. This case represents possible association of SARS-CoV-2 infection and GBS with good clinical outcome.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Estudios de Seguimiento , Síndrome de Guillain-Barré/tratamiento farmacológico , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Factores Inmunológicos/uso terapéutico , Masculino , Persona de Mediana Edad , SARS-CoV-2 , Tiempo
16.
J Med Case Rep ; 15(1): 219, 2021 Apr 28.
Artículo en Inglés | MEDLINE | ID: covidwho-1208393

RESUMEN

BACKGROUND: Coronavirus disease 2019 (COVID-19) is a global pandemic. The disease, typically characterized by bilateral pulmonary infiltrates and profound elevation of inflammatory markers, can range in severity from mild or asymptomatic illness to a lethal cytokine storm and respiratory failure. A number of recognized complications of COVID-19 infection are described in the literature. Common neurological complications include headache and anosmia. Guillain-Barré syndrome (GBS) is an uncommon complication described in isolated case reports. However, a causal relationship has yet to be established. This case report adds to the growing body of evidence that GBS is a potential COVID-19 complication. CASE PRESENTATION: A 70-year-old Caucasian woman with recently diagnosed COVID-19 infection presented to the emergency department with 4 days of gradually worsening ascending lower extremity weakness. Exam revealed bilateral lower extremity weakness, mute reflexes, and sensory loss. Soon after starting intravenous administration of immunoglobulin (IVIG), the patient developed respiratory distress, eventually requiring intubation. She remained intubated for the duration of her IVIG treatment. After five rounds of treatment, the patient was successfully extubated and transferred to acute rehab. Following 4 weeks of intense physical therapy, she was able to walk with assistance on room air. CONCLUSION: At the present time, this is one of the few reports of acute inflammatory demyelinating polyneuropathy (AIDP) or GBS associated with COVID-19 in the United States. It is unclear whether a causal relationship exists given the nature of the syndrome. However, in light of the growing number of reported cases, physicians should be aware of this possible complication when evaluating COVID-19 patients.


Asunto(s)
COVID-19 , Síndrome de Guillain-Barré , Anciano , COVID-19/complicaciones , COVID-19/diagnóstico , COVID-19/epidemiología , Femenino , Síndrome de Guillain-Barré/virología , Humanos , Estados Unidos/epidemiología
17.
Pediatr Infect Dis J ; 40(6): e236-e239, 2021 06 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1203763

RESUMEN

Neurologic manifestation of coronavirus disease 2019 (COVID-19) in children is evolving with time. We are reporting a young girl who presented to us with acute febrile illness followed by acute onset severe flaccid paralysis requiring prolonged intensive care unit stay and ventilator support. She was evaluated extensively and found to be positive for COVID serology, and neuroimaging revealed features of longitudinally extensive transverse myelitis (LETM) with enhancing cauda equina nerve roots, suggesting Guillain-Barré Syndrome (GBS). She failed to respond to immune suppressive therapy and needed plasma exchange for recovery. Like other common viral illnesses, COVID-19 can also act as a trigger for GBS-like illness and LETM, and we need to suspect these diagnoses in the cases with COVID-19 infection in compatible cases. This is probably the first pediatric case with concurrent GBS and LETM secondary to COVID-19 infection.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , COVID-19/diagnóstico , COVID-19/inmunología , Prueba Serológica para COVID-19 , Niño , Femenino , Síndrome de Guillain-Barré/inmunología , Humanos , Mielitis Transversa/inmunología , SARS-CoV-2/aislamiento & purificación
18.
J Neuroimmunol ; 355: 577577, 2021 06 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1188801

RESUMEN

OBJECTIVE: The systematic review aimed to determine demographic characteristics, clinical features, lab evaluation, management and complications of the studies focusing on Guillain-Barre syndrome (GBS) as a sequele of novel coronavirus (COVID-19) infection. METHODS: After protocol registration, PubMed, Web of Science and Cumulative Index to Nursing & Allied Health Literature (CINHAL) databases were searched for relevant articles using MeSH key-words and imported into referencing/review softwares. The data, regarding demographic and clinical characteristics, diagnostic workup and management, was analyzed in International Business Machines (IBM) Statistics SPSS 21. Many statistical tests, such as t-test and the Mann-Whitney U test, were used. P < 0.05 was considered significant. RESULTS: We identified 64 relevant articles. The mean age of the patients was 56 ± 16 years; the majority were males (64.9%). Among the neurological findings, paresthesia was the most typical symptom (48.9%). Most of the patients had been diagnosed by reverse transcriptase-polymerase chain reaction (RT-PCR) (69.2%). Two-third of the patients received immunoglobulins (IVIg) (77.7%). Although functions recovered in most patients, there were four patients with facial diplegia during follow-up (4.26%). Acute inflammatory demyelinating polyneuropathy (AIDP) was more likely to be associated with paresis of the lower extremity (p < 0.05) and higher levels of glucose on cerebrospinal fluid (CSF) analysis (p < 0.05). These patients were more likely to receive IVIg (p < 0.05) and develop respiratory insufficiency, subsequently (p < 0.05). CONCLUSIONS: GBS is being recognized as one of the many presentations of the COVID-19 infection. Although the common form is AIDP that might lead to complications, other variants are possible as well, and more studies are needed to focus on those subvariants.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Humanos , SARS-CoV-2
19.
J Neurol ; 268(4): 1191-1194, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: covidwho-1148889

RESUMEN

Presented herein is a severe case of SARS-CoV-2 associated Guillain-Barré syndrome (GBS), showing only slight improvement despite adequate therapy. To date, only few cases of GBS associated with this infection have been described. This case report summarizes the insights gain so far to GBS with this antecedent trigger. So far, attention has mostly focused on complications of the CNS involvement. Taking into account that GBS can cause a considerable impairment of the respiratory system, clinicians dealing with SARS-CoV-2 positive-tested patients should pay attention to symptoms of the peripheral nervous system. As far as we know from this reported case and the review of the current literature, there seems to be no association with antiganglioside antibodies or a positive SARS-CoV-2 RT-PCR in CSF. An obvious frequent occurrence of a bilateral facial weakness or bilateral peripheral facial diplegia should be emphasized.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/virología , Femenino , Síndrome de Guillain-Barré/fisiopatología , Humanos , Persona de Mediana Edad , SARS-CoV-2
20.
Arch Iran Med ; 23(10): 718-721, 2020 10 01.
Artículo en Inglés | MEDLINE | ID: covidwho-1115682

RESUMEN

Guillain-Barré syndrome (GBS) is a neurological disorder accompanied by several neurological signs and symptoms including progressive weakness and diminished or decreased reflexes. GBS was reported as one of the several neurological complications in MERS-CoV and SARS-CoV outbreaks. Several studies have reported GBS as a neurological complication in recent COVID-19 outbreak. We report on the case of a 55-years -old female who was hospitalized with dyspnea, dry cough, and myalgia. She developed Acute Motor & Sensory Axonal Neuropathy (AMSAN), a rare variant of GBS signs and symptoms including decreased muscle strength and pinprick sensation in both lower extremities during her hospitalization.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/complicaciones , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/virología , Neumonía Viral/complicaciones , COVID-19 , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/terapia , Femenino , Síndrome de Guillain-Barré/terapia , Humanos , Persona de Mediana Edad , Pandemias , Neumonía Viral/diagnóstico , Neumonía Viral/terapia , SARS-CoV-2
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA